Hjem › Tripelnegativ brystkreft › New Mexico
Kliniske studier for Tripelnegativ brystkreft i New Mexico
3 studier for Tripelnegativ brystkreft søker deltakere på steder i New Mexico.
Byer i New Mexico
Offisiell studietekst (engelsk)
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- New Mexico Oncology Hematology Consultants Ltd. ( Site 0019), Albuquerque
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06841354Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- New Mexico Oncology Hematology Consultants Ltd. ( Site 0090), Albuquerque
- CHRISTUS St. Vincent Regional Cancer Center ( Site 0118), Santa Fe
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06393374Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- University of New Mexico, Albuquerque
- San Juan Oncology Associates, Farmington
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT05633654Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.